Clinical Trials Logo

Neoplasms, Colorectal clinical trials

View clinical trials related to Neoplasms, Colorectal.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05643989 Recruiting - Clinical trials for Neoplasms,Colorectal

Self-expandable Metal Stent (SEMS) Endoscopic Placement for Malignant Colonic Obstruction Therapy

PATENCY
Start date: November 1, 2019
Phase: N/A
Study type: Interventional

Compare the effectiveness of Self-expandable metal stent (SEMS) and diverting stoma formation for the bowel preparation as a bridge to surgical treatment of patients with MCO.

NCT ID: NCT05358249 Recruiting - Colorectal Cancer Clinical Trials

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KontRASt-03
Start date: October 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

NCT ID: NCT04892342 Recruiting - Neoplasms, Breast Clinical Trials

Study of ESG401 in Adults With Solid Tumors

Start date: September 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and efficacy of ESG401 administered in 21-day treatment cycles at a dose selected in Phase I. Tumor types in the study will include: cervical, colorectal, endometrial, ovarian, esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell, small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast cancer (TNBC) and metastatic urothelial cancer (mUC).

NCT ID: NCT04593407 Recruiting - Clinical trials for Neoplasms, Colorectal

Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.

intERsection
Start date: November 3, 2020
Phase: N/A
Study type: Interventional

EMR and ESD are both effective and safe and are associated with a very low risk of procedure related mortality when performed for colorectal laterally spreading lesions (LSL). Some kind of LSLs have a low risk of submucosal invasive carcinoma (SMIC) or these foci are found in well demarcated areas of the tumor. This is the case of the non-granular flat elevated (LSN-NG-FE) and the LSLs-G mixed subtypes. The investigators aim to assess if piecemeal EMR (the older technique) for LSLs-G mixed type > 30 mm and LSLs-NG FE type > 20 mm is not inferior to ESD (the new treatment) for the need of additional surgery in the mid-term.